Viveve is a women’s sexual health company based in Sunnyvale, California. The company is focused on the commercialization of a revolutionary, non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue.
Viveve treats the condition of vaginal laxity, which results from over stretching the vaginal introital (opening) tissue during childbirth. As a result of this tissue damage, women can experience a decrease in sexual satisfaction and physical sensation during intercourse, which may adversely impact their sexual health and quality of life.
The Viveve System uses patented, radio frequency (RF) technology to tighten the tissues around the vaginal introitus or opening. Unlike surgical vaginal reconstruction procedures, the Viveve System can tighten vaginal tissue without incisions, tissue ablation, or anesthesia. In addition, the procedure requires only a 30-minute treatment in a physician’s office. Given the non-surgical nature of the treatment, patients experience minimal post-treatment restrictions and recovery times.
The Viveve Treatment has been tested in two prospective clinical trials; one in the U.S. and one in Japan. The goal was to assess the safety and effectiveness of the treatment. In both studies, sexual function and vaginal tightness improved significantly, to pre-childbirth levels, and was sustained through 12 months. The Viveve System is currently approved in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the United States.
The company’s goal is to increase awareness of the Viveve Treatment option and to spark the conversation between women and their doctors about vaginal laxity and sexual health. Discussing the changes a woman experiences after childbirth is the first step in identifying her concerns and discussing options to improve her quality of life. Because sex may change after kids, how it feels, doesn’t have to.